Table 1.
Demographic, Laboratory, and Clinical Data of the Cohort of Patients With ALI/ALF
| Variable | Patients With ALI (n = 297) n (%) or mean ± SD | Patients With ALF (n = 379) n (%) or mean ± SD | Patients With ALI/ALF (n = 676) n (%) or mean ± SD |
|---|---|---|---|
| Demographics | |||
| Age (years) | 38.6 ± 15.4 | 42.4 ± 15.9 | 40.8 ± 15.8 |
| Gender (female) | 176 (59.3) | 242 (63.9) | 418 (61.8) |
| Race (Caucasian) | 225 (75.8) | 278 (73.5) | 503 (74.4) |
| APAP etiology | 164 (55.2) | 144 (38.0) | 308 (45.6) |
| Laboratory Data on Hospital Admission | |||
| Platelet count (×109/L) | 155.9 ± 80.9 | 137.0 ± 86.7 | 145.2 ± 86.7 |
| INR | 2.8 ± 1.3 | 3.6 ± 1.9 | 3.3 ± 1.7 |
| WBC (×109/L) | 8.4 ± 4.3 | 12.2 ± 8.1 | 10.5 ± 6.9 |
| Albumin (g/dL) | 3.0 ± 0.6 | 2.7 ± 0.6 | 2.8 ± 0.6 |
| Lactate (mg/dL) | 2.6 ± 1.9 | 4.7 ± 3.9 | 4.0 ± 3.5 |
| Creatinine (mg/dL) | 1.3 ± 1.2 | 2.1 ± 1.7 | 1.7 ± 1.6 |
| Phosphate (mg/dL) | 2.7 ± 1.4 | 3.5 ± 1.9 | 3.2 ± 1.8 |
| Bicarbonate (mg/dL) | 23.6 ± 4.0 | 21.1 ± 5.4 | 22.1 ± 5.0 |
| Clinical Features on Hospital Admission | |||
| Hepatic encephalopathy (high grade) (%) | 0 (0.0) | 170 (44.9) | 170 (25.2) |
| SIRS (%) | 93 (31.3) | 240 (63.3) | 333 (49.3) |
| Infection (%) | 21 (7.1) | 63 (16.6) | 84 (12.4) |
| Anticoagulants (%) | 11 (3.7) | 21 (5.5) | 32 (4.7) |
| Interventions After Admission | |||
| RBC transfusion (%) | 10 (3.4) | 82 (21.6) | 92 (13.6) |
| RRT (%) | 18 (6.1) | 153 (40.4) | 171 (25.3) |
| Vasopressors (%) | 14 (4.7) | 158 (41.7) | 172 (25.4) |
| Outcome | |||
| Bleeding (%) | 10 (3.4) | 40 (10.6) | 50 (7.4) |
| 21‐day transplant‐free survival (%) | 273 (91.9) | 210 (55.4) | 483 (71.5) |
| Liver transplantation within 21 days (%) | 9 (3.0) | 62 (16.4) | 71 (10.5) |
| Death within 21 days (%) | 15 (5.1) | 112 (29.6) | 127 (18.8) |
Abbreviations: APAP, acetaminophen; RRT, renal replacement therapy; and WBC, white blood cell.